Why Penumbra Stock Zoomed 4% Higher Today

The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares. News about one of Penumbra's (PEN 4.02%) development programs and an analyst's price target raise combined to boost the medical device company's stock on Monday. Its price rose by over 4%, giving the stock a clear victory over the S&P 500 index, which increased by 0.8%. Good news from the lab Penumbra announced that it has completed patient enrollment for a clinical trial to evaluate its Penumbra ...